Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Status: No longer recruiting

Protocol number: BH18387

Sponsor: Hoffmann-La Roche

Company division: Pharmaceutical

Official Scientific Title: An open-label study of the effect of long-term Mircera on hemoglobin levels in patients with chronic renal anemia

Brief summary: This single arm study will assess the long term efficacy, safety and tolerability of intravenous (iv) or subcutaneous (sc) Mircera in chronic kidney disease patients with renal anemia. Eligible patients will be those who are currently receiving stable maintenance therapy with Mircera in Phase II or III clinical studies. They will continue to receive Mircera at the same weekly dose and by the same route of administration (sc or iv) every 2 or every 4 weeks, as in the qualifying studies. The anticipated time on study treatment is 2+ years, and the target sample size is 500+ individuals. Target sample size is 1800.

Study phase: III

Study type: Interventional; Treatment; Non-Randomized; Open Label; Uncontrolled; Parallel; Safety/Efficacy study

Condition: Anemia

Intervention type: Drug

Intervention name: methoxy polyethylene glycol-epoetin beta [Mircera]

Primary outcome: 1. Hb concentration over time Time frame: Throughout study

Key secondary outcomes: 1. Vital signs, AEs, laboratory parameters Time frame: Throughout study

Inclusion criteria:

  • adult patients >=18 years of age;
  • chronic renal anemia;
  • currently receiving Mircera as part of a clinical study.

Exclusion criteria:

  • women who are pregnant, breastfeeding or using unreliable birth control methods;
  • administration of another investigational drug planned during the study period.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: September, 2004

Trial registration date: 05/23/2005

Date last updated: 8/19/2008


Link to trial result

This trial was conducted at the following locations:

Australia

  • Gosford
  • Liverpool
  • Melbourne
  • Parkville
  • Sydney
  • Woolloongabba

Austria

  • Graz

Belgium

  • Aalst
  • Bruxelles
  • Gent
  • Hasselt
  • Leuven
  • Liege

Czech Republic

  • Liberec
  • Ostrava
  • Plzen

Denmark

  • Aalborg
  • Odense
  • Roskilde

Finland

  • Hus
  • Tampere

France

  • Amiens
  • Bayonne
  • Bordeaux
  • Boulogne
  • Cabestany
  • Caen
  • Chambery
  • Colmar
  • Hyeres
  • La Tronche
  • Limoges
  • Lyon
  • Nantes
  • Nimes
  • Paris
  • Perpignan
  • Poitiers
  • Rouen
  • Saint Ouen
  • Saint-Germain-En-Laye
  • Tarbes
  • Toulouse

Germany

  • Berlin
  • Dortmund
  • Erlangen
  • München
  • Nürnberg
  • Stuttgart
  • Villingen-Schwenningen
  • Wiesbaden
  • Wuppertal

Greece

  • Alexandroupolis
  • Ioannina
  • Larissa
  • Piraeus
  • Thessaloniki

Hungary

  • Budapest
  • Debrecen
  • Miskolc
  • Pecs

Italy

  • Bergamo
  • Cagliari
  • Como
  • Cremona
  • Cuneo
  • Genova
  • Lecco
  • Livorno
  • Lodi
  • Messina
  • Modena
  • Pavia
  • Prato
  • Reggio Calabria
  • Venezia

Mexico

  • Cuernavaca
  • Mexico City

Netherlands

  • Heerlen

Norway

  • Trondheim

Panama

  • Panama City

Poland

  • Gdansk
  • Gdynia
  • Kielce
  • Krakow
  • Lodz
  • Poznan
  • Rzeszow
  • Szczecin
  • Warszawa
  • Wolomin
  • Wroclaw

Russian Federation

  • Moscow
  • St Petersburg

South Africa

  • Cape Town
  • Durban
  • Soweto

Spain

  • Alcorcon
  • Alicante
  • Almería
  • Badalona
  • Barcelona
  • Córdoba
  • La Coruna
  • Madrid
  • Malaga
  • Oviedo
  • Palma de Mallorca
  • Salamanca
  • Santander
  • Santiago de Compostela
  • Sevilla

Sweden

  • Huddinge
  • Umea

Switzerland

  • Aarau
  • Lausanne

Thailand

  • Bangkok
  • Chiang Mai
  • Chonburi
  • Phitsanulok

United Kingdom

  • Belfast
  • Cambridge
  • Dundee
  • Exeter
  • Glasgow
  • Leicester
  • London
  • Salford
  • Swansea

United States

  • Birmingham, AL
  • Montgomery, AL
  • Hot Springs, AR
  • Encino, CA
  • Irvine, CA
  • Los Alamitos, CA
  • Los Angeles, CA
  • Monterey Park, CA
  • Mountain View, CA
  • Sacramento, CA
  • San Diego , CA
  • San Francisco, CA
  • Stanford, CA
  • Colorado Springs, CO
  • Denver, CO
  • Lakewood, CO
  • Stamford, CT
  • Ocala, FL
  • Pembroke Pines, FL
  • Augusta, GA
  • Honolulu, HI
  • Maywood, IL
  • Louisville, KY
  • Baton Rouge, LA
  • Shreveport, LA
  • Boston, MA
  • Springfield, MA
  • Detroit, MI
  • Kalamazoo, MI
  • Brooklyn Center, MN
  • Columbus, MS
  • Tupelo, MS
  • St Louis, MO
  • Hackensack, NJ
  • Paterson, NJ
  • Albuquerque, NM
  • Bronx, NY
  • Brooklyn, NY
  • Flushing, NY
  • Great Neck, NY
  • Mineola, NY
  • New York, NY
  • Chapel Hill, NC
  • Mount Airy, NC
  • Raleigh, NC
  • Cincinnati, OH
  • Toledo, OH
  • Oregon City, OR
  • Portland, OR
  • Allentown, PA
  • Erie, PA
  • Lewistown, PA
  • Philadelphia, PA
  • Pittsburgh, PA
  • Ponce, PR
  • Columbia, SC
  • Orangeburg, SC
  • Chattanooga, TN
  • Nashville, TN
  • Austin, TX
  • Dallas, TX
  • Houston, TX
  • Burlington, VT
  • Fairfax , VA
  • Norfolk , VA
  • Salem, VA
  • Morgantown, WV

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply